Which biopharmas are best positioned for 2018? Leerink pegs Vertex and Alexion

2nd January 2018 Uncategorised 0

Last year was tough for drugmakers, as investors shunned Big Pharma companies facing new competition for their blockbusters and insurers loudly protested pricing of newer products. More of the same is ahead, analysts figure, but some companies are better able to handle it.

More: Which biopharmas are best positioned for 2018? Leerink pegs Vertex and Alexion
Source: fierce